Omnicell (NASDAQ:OMCL) PT Raised to $41.00 at Wells Fargo & Company

Omnicell (NASDAQ:OMCL) had its target price boosted by research analysts at Wells Fargo & Company from $30.00 to $41.00 in a research note issued on Monday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential downside of 5.57% from the company’s current price.

OMCL has been the subject of several other research reports. JPMorgan Chase & Co. upped their price target on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Benchmark reiterated a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $26.00 to $39.00 in a research report on Friday, August 2nd. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Bank of America boosted their price objective on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $41.33.

Omnicell Stock Up 1.9 %

Shares of NASDAQ OMCL traded up $0.80 during midday trading on Monday, hitting $43.42. 20,284 shares of the stock traded hands, compared to its average volume of 521,034. The company has a market cap of $1.99 billion, a PE ratio of -92.72, a P/E/G ratio of 47.35 and a beta of 0.83. Omnicell has a one year low of $25.12 and a one year high of $45.84. The business has a 50 day moving average price of $43.04 and a two-hundred day moving average price of $33.86. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. During the same quarter in the previous year, the company posted $0.29 earnings per share. The company’s quarterly revenue was down 7.4% on a year-over-year basis. On average, equities analysts predict that Omnicell will post 0.64 EPS for the current year.

Hedge Funds Weigh In On Omnicell

A number of institutional investors have recently added to or reduced their stakes in the business. Creative Planning increased its stake in Omnicell by 23.1% in the 3rd quarter. Creative Planning now owns 11,667 shares of the company’s stock worth $509,000 after acquiring an additional 2,188 shares during the last quarter. Diversified Trust Co increased its stake in Omnicell by 43.0% in the 3rd quarter. Diversified Trust Co now owns 21,966 shares of the company’s stock worth $958,000 after acquiring an additional 6,602 shares during the last quarter. GAMMA Investing LLC increased its stake in Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the last quarter. SG Americas Securities LLC increased its stake in Omnicell by 67.3% in the 3rd quarter. SG Americas Securities LLC now owns 25,157 shares of the company’s stock worth $1,097,000 after acquiring an additional 10,116 shares during the last quarter. Finally, Algert Global LLC increased its stake in Omnicell by 9.8% in the 2nd quarter. Algert Global LLC now owns 51,942 shares of the company’s stock worth $1,406,000 after acquiring an additional 4,617 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.